Medtech Product Launch: What Actually Works

I'm Kurt Schmidt, founder of Schmidt Consulting Group, and I've spent years watching B2B services firms and their clients get product launches exactly backward. They lead with features, assume they know what the market wants, and skip the alignment work that determines whether a launch lives or dies before it ever reaches a customer. In the medtech product launch world, that backward approach is especially costly.

I recently had a deep conversation with Bob Freitag, a marketing leader who has spent over 30 years running launches in medtech, industrial, and other regulated markets. What he described reinforced everything I've observed working with services firms that support regulated-industry clients: the companies that nail launches treat them as strategic alignment exercises first and marketing executions second.

This article is my synthesis of what actually works. The process is transferable well beyond medical devices. If you're launching anything in a regulated, multi-stakeholder environment, this is the playbook.

---

Why Do Most Medtech Product Launches Fail Before They Hit the Market?

The internal team is usually the problem.

When a product has been in development for five, seven, sometimes ten years, the people closest to it can't see it clearly anymore. Engineers see the specs. Regulatory teams see the compliance requirements. Sales sees the feature set they've been carrying in their heads for years. And marketing is often handed a brief that reflects all three of those internal views rather than what the market actually needs to hear.

I've worked with firms that went through an entire launch cycle and discovered, too late, that their customers were describing the product's core value in language that looked nothing like the internal messaging. That's a failure of discovery, and it's preventable.

The fix starts before a single line of copy is written. You need structured, individual interviews with both your internal stakeholders and your target customers, conducted separately, so people speak honestly. Group sessions produce consensus. Individual interviews produce signal.

Once you have both sets of input, the real work is finding where the internal story and the market reality diverge. Those gaps are where launches go sideways.

---

What Does a High-Stakes Launch Leadership Team Actually Look Like?

Most organizations default to department heads when they form launch committees. That's the wrong call.

The people who move a message inside an organization are often the ones others come to with questions. They're in the trenches. When those people believe in a launch direction, they carry the message organically to their peers. When they don't, no amount of top-down communication fixes the internal disconnect.

A well-structured medtech product launch team pulls those influential mid-level operators into the process from day one. Their job isn't just to receive the strategy. Their job is to be the internal voice of it. They attend the discovery process, understand the market feedback behind the decisions, and can explain the "why" to colleagues who weren't part of those conversations.

I'd add one more thing: the success criteria for the launch must be defined in writing before any creative work starts. What does winning look like, and by when? That definition has to be shared, debated, and agreed upon by the whole cross-functional group. Without it, everyone evaluates the work through a different lens, and alignment collapses the moment you're under deadline pressure.

This is also where I've seen ego derail otherwise strong teams. A senior leader with a strong opinion about what the message should be, formed over years of product development, can crowd out the signal from the market. The answer is a process rigorous enough that the market data does the arguing for you. When customers tell you something in their own words, it's much harder for an internal stakeholder to override it than if you're just presenting an agency's recommendation.

---

How Do You Develop and Test a Strategic Narrative in a Regulated Market?

This is where most agencies shortcut the process, and where the biggest mistakes happen in a medtech product launch.

A strategic narrative is the overarching story you're asking the market to believe about your product and company. It sits above the tagline, above the campaign, above the individual pieces of content. It's the "why this, why now, why us" distilled into a handful of words that has to resonate with physicians, nurses, hospital administrators, distributors, and sometimes patients simultaneously.

The right process generates multiple narrative directions first (I typically see five to seven viable territories to evaluate) and then narrows them through two filters: internal alignment and external validation.

The internal filter asks whether each narrative is meaningful, differentiated, and something the company can actually deliver on. Teams debate these. The goal is to get to two or three directions that everyone on the team can genuinely support.

Then you test externally before you commit. You go back to the target market with those three directions and listen. What resonates, and why? What language do customers use when they respond? What's the gap between the benefit you thought they'd care about and the one they actually do?

Bob Freitag made a point in our conversation that I keep coming back to: even experienced teams, after decades of doing this, are regularly surprised by what wins in the market. The direction they were most confident about doesn't always land, which is a reminder that market testing is a discipline.

The practical payoff of this process is internal alignment around a message the market has already validated. You're not asking your sales team to believe in a direction because someone in marketing said it was right. You're showing them the feedback.

---

Why Does Emotional Messaging Outperform Feature Lists in Complex B2B Markets?

Because every human in the purchase chain, regardless of their title or technical sophistication, makes decisions emotionally and justifies them rationally afterward.

I've seen this play out across dozens of engagements. The B2B buyer who argues they're completely data-driven is still responding to whether they feel heard, whether the vendor seems to understand their world, and whether buying this thing makes them look smart or exposed in front of their colleagues.

In medtech specifically, the purchase chain is long. A medical device might need to win over the physician who wants to use it, the nursing staff who'll operate it, the hospital administrator who has to justify the capital expenditure to a value analysis committee, and distributors who have to decide whether to carry it at all. Each of those audiences has a different rational checklist. But every single one of them responds first to whether the message connects with their reality.

The cardiac surgeon example is instructive here. When interventional cardiologists started generating more hospital revenue, a subset of cardiac surgeons felt sidelined. That feeling had nothing to do with device specs. A company with a mechanical heart valve product tapped into that emotional reality, repositioned around the cardiac surgery community rather than the device's features, and went from 2% to 18% market share in a stagnant market over several years. The product hadn't changed.

In a separate case, a perfusion device launched with the lead message "designed by perfusionists" rather than the typical company-first framing. The company's features were strong, but the feature story wasn't what moved the market. What moved it was that the audience felt like they'd been part of creating the product. That sense of collaboration generated a groundswell that pure benefit communication would never have produced.

Both examples follow the same logic: find the emotional truth first, then let the features do their job as rational justification.

This maps directly to how Geoffrey Moore frames crossing the chasm in technology markets. The early adopters you need to move are responding to something beyond the spec sheet. Connecting with that "something" is the work.

---

How Do You Manage Multi-Audience Messaging Across a Long Sales Cycle?

The medtech product launch problem is rarely a messaging problem in isolation. It's a distribution and amplification problem.

You can have a brilliant strategic narrative and still fail if your sales team can't articulate it, your distributors don't know it, and your key opinion leaders (KOLs) are improvising their own version of the story at every conference.

KOLs matter enormously in regulated markets. A respected physician or specialist with an engaged following (even 30,000 followers on LinkedIn or a conference speaking circuit) carries far more weight with a target audience than a brand campaign. The practical question is how you equip them. What assets do they need? What language do you want reinforced? You can't control what they say, but you can make it easy for them to say the right things by giving them the building blocks.

The same logic applies to hospital value analysis committees, which I find underserved in most launch plans. These committees typically meet on multi-year cycles, sometimes every three years, and a company may get one presentation window. The people presenting are often internal champions at the hospital. That means you need to build a case so clear and strong that someone who didn't develop it can carry it into a room and win.

I'd also flag patient communities here. In pharma this is well established, but in medtech it's catching up fast. A patient who found information online, understood what a quiet mechanical heart valve meant for their daily life, and specifically requested it when speaking to their physician. That's a patient-driven sale the company might never have expected. It happened because someone was paying attention to what patients actually cared about, not just what physicians needed to know.

This connects directly to and how firms structure education-forward digital presence. The era of "call us to learn more" is over in regulated markets. The sophisticated buyer arrives informed.

---

What Are the Biggest Structural Mistakes in a Medtech Product Launch?

Four patterns come up repeatedly in my experience working with services firms in this space.

First, launching before internal alignment is complete. External market gravity is easy to think about; internal market gravity is harder to see. Two competing internal narratives, or one senior leader who's quietly unconvinced, can quietly sabotage a launch that looks fine on the surface.

Second, skipping external message testing. Teams are too close to the product. They've heard their internal story so many times it sounds obvious. It rarely is. positioning strategy for services covers this in more depth, but the short version is that your confidence in a direction is inversely correlated with how often you've heard it internally.

Third, leading with the company rather than the audience. "We built this and here's why it's great" is a harder story to tell than "we understand your world and here's what we made for you." The perfusion device example is the clearest illustration I can offer. Putting the audience first, in the literal first line of the marketing, changed the entire market's relationship with the product.

Fourth, under-investing in enabling the sales channel. Distributors and sales reps are multiplicative. If they understand the message and believe it, a hundred conversations go well. If they don't, they improvise, and the brand story fragments across every customer interaction.

I covered the topic of launch readiness and sales channel alignment in more depth on The Schmidt List, and I'd recommend giving it a listen if you're working through a launch right now.

---

Key Takeaways

• Define success criteria in writing before any creative work begins. Shared clarity on what "winning" looks like by a specific date is the foundation of cross-functional alignment.
• Conduct individual interviews separately with internal stakeholders and target customers. Group sessions produce consensus; individual interviews produce signal.
• Generate multiple strategic narrative directions, then narrow through both internal alignment and external market testing. The direction you're most confident about internally is often not the one the market selects.
• Lead with the audience's emotional reality before the product's features. Features justify the decision. Emotion makes it.
• Equip everyone in the sales chain: distributors, KOLs, and internal champions who carry the message to value analysis committees. A brilliant message that only lives in a brand deck doesn't exist in the market.
• Build patient and end-user education into the digital presence. The informed buyer is the norm in regulated markets, and content that meets them where they are creates pull that sales alone can't generate.

The firms I've seen win in regulated markets treat launch not as a marketing event but as a sustained alignment operation. go-to-market strategy If your launch plan doesn't address internal alignment with the same rigor as external messaging, the external work is already compromised.

One question to sit with as you build your plan: who inside the customer's organization will carry your story into the rooms you'll never get access to, and have you given them everything they need?